Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04714372 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | completed | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT00285259 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | completed | Phase 2 | 112 | Astellas Pharma IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06410586 | Integrative Korean Medicine Treatment for Pediatrics After Traffic Accident: Retrospective Chart Review Study and Survey | completed | — | 57 | Jaseng Medical FoundationOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03941769 | 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | completed | Phase 1 / Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04151706 | CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML | completed | Phase 2 | 7 | Robert LowskyOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04788472 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL | completed | Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04943757 | Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies(PTBCy) | completed | Phase 2 | 50 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05724030 | Use of Integrated Pulmonary Index Monitorisation in Children Undergoing Botulinum Toxin Injection | completed | N/A | 69 | Kocaeli UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03441048 | Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03595800 | Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen(HaploMUD-RIC) | completed | Phase 3 | 9 | Institut Paoli-CalmettesOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06624007 | Applying Pediatric Nursing Excellence Model to Nurses in Orthopedic Surgery Care of Children | completed | N/A | 100 | Jouf UniversityOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT02926586 | Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | completed | Phase 4 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT02768792 | High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML | completed | Phase 2 | 38 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04570709 | RN-Led Palliative and Supportive Care Intervention | completed | N/A | 67 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04081753 | Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy(REMEDY) | completed | N/A | 12 | Augusta UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT01838395 | Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients | completed | Phase 2 | 42 | BioLineRx, Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT02484391 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | completed | Phase 1 | 48 | Wake Forest University Health SciencesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04017546 | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS | completed | Phase 1 | 14 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04500587 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | completed | Phase 1 | 39 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT04827069 | A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML) | completed | Phase 1 | 75 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05557110 | Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL | completed | Phase 2 | 35 | Chen SuningOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04267081 | Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening(VenEx) | completed | Phase 2 | 104 | Helsinki University Central HospitalOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT04472286 | Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors(HBHL) | completed | — | 40 | University of NebraskaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT02920008 | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | completed | Phase 3 | 302 | Astex Pharmaceuticals, Inc.INDUSTRY | 15 | Aug 28, 2024 | clinicaltrials |
| NCT06209528 | Assessing Neurophysiological and Cognitive Function in School Children(WIS) | completed | — | 17 | Life UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02096055 | Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | completed | Phase 3 | 227 | Astex Pharmaceuticals, Inc.INDUSTRY | 10 | Aug 27, 2024 | clinicaltrials |
| NCT05298930 | Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation(EVAADE) | completed | N/A | 15 | Centre Leon BerardOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03372291 | Psychological Intervention Mobile App for Patients With AML | completed | N/A | 60 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 2 | Aug 13, 2024 | clinicaltrials |
| NCT03275636 | Haploidentical Donor vs mMUD in Hematological Malignancies(HAMLET) | completed | Phase 2 / Phase 3 | 98 | DKMS gemeinnützige GmbHOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)(QuANTUM-First) | completed | Phase 3 | 539 | Daiichi SankyoINDUSTRY | 28 | Aug 6, 2024 | clinicaltrials |
| NCT05035615 | Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer | completed | — | 332 | Becton, Dickinson and CompanyINDUSTRY | 5 | Aug 6, 2024 | clinicaltrials |
| NCT03813186 | Effect of Food on Blood Levels of ASTX727 | completed | Phase 1 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02113982 | Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 138 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02323022 | Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 618 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06527781 | A Study of PD5K3 in Healthy Adult Volunteers | completed | Phase 1 | 28 | Chongqing Peg-Bio Biopharm Co., Ltd.INDUSTRY | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03902665 | Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 | completed | Phase 2 | 19 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04311216 | Shoulder Instability in Children: Muscle Activity and Movement | completed | — | 30 | Robert Jones and Agnes Hunt Orthopaedic and District NHS TrustOTHER_GOV | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05250869 | Comparative Quantification of MTX and Its Metabolites Post Glucarpidase | completed | — | 4 | Charite University, Berlin, GermanyOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT04901416 | Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS | completed | Phase 1 | 8 | Coeptis TherapeuticsINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT01523977 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL(CRAD001NUS175T) | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05850013 | The Measurement of Vital Signs in Children by Lifelight® Software in Comparison to the Standard of Care(VISION-Jr) | completed | — | 504 | Xim LimitedINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT02626715 | Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS | completed | Phase 2 | 21 | Randy WindreichOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT00557193 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 218 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT06489236 | Effectiveness of an Intervention on Vaccine Hesitancy Among Pediatric Nurses and Pediatricians | completed | N/A | 142 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT02400281 | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | completed | Phase 1 / Phase 2 | 28 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04969601 | Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings(PACIFIC) | completed | Phase 1 / Phase 2 | 76 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04835519 | Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 5 | Beijing Boren HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06463639 | FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia | completed | — | 1,213 | National Taiwan University HospitalOTHER | 1 | Jun 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 24, 2024source: clinicaltrials